DexComRegister for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
DexCom (DXCM) reported revenue of $1.19B in Q1 2026.
DexComContinuous glucose monitoring pure-play (G7, Stelo over-the-counter sensor). Physicians increasingly pair CGM with GLP-1 therapy, making Dexcom the monitoring layer around the drug class; G7 data in non-insulin type 2 patients showed A1C and weight benefits at one year.
Q2 2024-Q1 2026
Q2 2024-Q1 2026
Q2 2024-Q1 2026
DexCom (DXCM) is a Medical - Devices company. Continuous glucose monitoring pure-play (G7, Stelo over-the-counter sensor). Physicians increasingly pair CGM with GLP-1 therapy, making Dexcom the monitoring layer around the drug class; G7 data in non-insulin type 2 patients showed A1C and weight benefits at one year. It was founded in 1999, is headquartered in San Diego, CA and employs about 11,100 people.
Track DexCom's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated July 30, 2026.
Sterling groups DexCom in the GLP-1 sector, alongside Ypsomed (YPSN.SW), Insulet (PODD) and West Pharmaceutical Services (WST).
If you are researching DexCom, also look at Ypsomed (YPSN.SW), Insulet (PODD) and West Pharmaceutical Services (WST). You can compare all of them side by side or browse the full GLP-1 sector on Sterling.